Atlas Trials

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Clinical trial NCT05535413 · RECRUITING

Trial details

NCT number
NCT05535413
Sponsor
Hunan Cancer Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic HER2 Negative Breast CarcinomaBrain MetastasesCapecitabineUDT1
Start date
2023-01-01
Primary completion
2024-10-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.